The stimulant medications widely prescribed to treat ADHD are still not meeting the demand, according to the Food and Drug Administration. The shortage has persisted for the second year, and various factors like growing demand and federal supply limitations are being blamed for it. The rise in ADHD medication prescriptions in the U.S. and globally post-COVID-19, supply chain issues, manufacturing problems, and decisions made by manufacturers have all contributed to the ongoing shortage, says the FDA.
The Drug Enforcement Administration (DEA) has set production limits for controlled substances, causing concerns that it is exacerbating the shortage. Although the agency asserts that this year’s limits will meet the growing demand for ADHD treatments, generic drugmakers say they have been unable to meet their federal quotas. The DEA raised its limits for methylphenidate after last year’s shortage began, but it also accuses some drugmakers of not producing up to their quotas. Additionally, the DEA plans to modify the process to minimize unused quotas, yet it is unclear whether these changes have addressed the shortages.
While brand-name ADHD medications like Adderall, Vyvanse, and Concerta are readily available, many generic manufacturers are struggling to keep up with the demand. According to the FDA, manufacturers of amphetamine mixed salts are still unable to meet overall demand, and Teva Pharmaceuticals reports continued unprecedented demand for its branded Adderall products. Similarly, there are ongoing shortages for methylphenidate and lisdexamfetamine dimesylate, affecting generic versions of Concerta and Vyvanse.
Patients facing shortages of their prescribed ADHD medication have limited options, including calling or visiting other pharmacies in search of supplies or discussing alternatives with their doctor. Switching to another medication can also pose risks and necessitates close monitoring by healthcare professionals. The regulations imposed on pharmacies concerning controlled substances can further complicate the search for these medications, exacerbated by limitations on stocking and distributing stimulants.
The shortage encompasses all three frequently prescribed ADHD stimulant medications: methylphenidate, amphetamine mixed salts, and lisdexamfetamine. The shortage is affecting both brand-name and generic medications, prompting patients and healthcare providers to adopt perseverance, flexibility, and creativity in dealing with these challenges.
